Free Trial
OTCMKTS:DSNKY

Daiichi Sankyo Q3 2026 Earnings Results & Report

Daiichi Sankyo logo
$17.68 -0.54 (-2.96%)
As of 11/10/2026 03:58 PM Eastern

Daiichi Sankyo beat analyst earnings expectations but missed on revenue in its Q3 2026 results, released January 29, 2026. The company reported EPS of $0.30 versus the $0.2504 consensus estimate, while revenue of $3.65 billion fell short of the $3.88 billion estimate by $232.10 million.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
Before Market Opens

Daiichi Sankyo EPS Results

Actual EPS
$0.30
Consensus EPS
$0.2504
Beat/Miss
Beat by +$0.0496
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 4 quarters

Daiichi Sankyo Revenue Results

Actual Revenue
$3.65 billion
Expected Revenue
$3.88 billion
Beat/Miss
Missed by -$232.10 million
YoY Revenue Growth
N/A

Upcoming Earnings

Daiichi Sankyo's next earnings date is estimated for Friday, January 29, 2027, based on past reporting schedules.

Conference Call Resources

Daiichi Sankyo Q3 2026 Earnings FAQ

Daiichi Sankyo (OTCMKTS:DSNKY) reported earnings of $0.30 per share for Q3 2026, beating the consensus estimate of $0.2504. The report was announced on Thursday, January 29, 2026.

Daiichi Sankyo reported revenue of $3.65 billion for Q3 2026, against a consensus estimate of $3.88 billion.

Daiichi Sankyo's next earnings date is estimated for Friday, January 29, 2027. MarketBeat tracks confirmed and estimated earnings dates for Daiichi Sankyo on the company's earnings history page.

Daiichi Sankyo Earnings Headlines

Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up After Earnings Beat
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
See More Daiichi Sankyo Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Daiichi Sankyo? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Daiichi Sankyo and other key companies, straight to your email.

About Daiichi Sankyo

Daiichi Sankyo (OTCMKTS:DSNKY) is a Japan-based pharmaceutical company that researches, develops, manufactures and markets medicines. Formed in 2005 through the merger of Sankyo and Daiichi Pharmaceutical, the company has a particular focus on oncology and also develops treatments in areas such as cardiovascular disease and other serious conditions.

Its portfolio includes Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate developed in collaboration with AstraZeneca, as well as medicines such as Lixiana (edoxaban) and Vanflyta (quizartinib). Daiichi Sankyo also invests in research and development, including antibody-drug conjugates and other targeted therapies.

Headquartered in Tokyo, Daiichi Sankyo serves patients and healthcare providers in Japan and international markets, including the United States and Europe. It works with partners in some markets to develop and commercialize medicines.

View Daiichi Sankyo Profile